What Kotra Pharma does

Kotra Pharma (M) Sdn Bhd is a Malaysian pharmaceutical manufacturer founded in 1982 and operating as a wholly-owned subsidiary of publicly listed Kotra Industries Berhad (Bursa Malaysia: KOTRA). The company manufactures and markets a broad portfolio spanning nutraceuticals (Appeton), prescription pharmaceuticals (Axcel for paediatric, dermatological, anti-infective, and gastroenterology care spanning 22 therapeutic classes; Vaxcel for sterile injectables including antibiotics, anticoagulants, anaesthetics, and proton-pump inhibitors), respiratory devices (Arite metered-dose inhalers), and OTC products (Creobic antifungals, AxPain paracetamol). Manufacturing is anchored by the RM210 million Kotra Pharma Technology Centre (KPTC) in Melaka — fully operational since 2013, PIC/S GMP certified, QbD-designed, and equipped for oral, topical, sterile injectable, MDI, and pre-filled syringe formats — with a sales and marketing office in Kuala Lumpur.

The company operates a hybrid B2B/B2C go-to-market: pharmaceutical sales representatives and hospital key account executives drive prescription adoption across clinics, pharmacies, and hospital formularies; medical detailing and conference participation engage healthcare professionals; OTC products move through pharmacy retail channels; and Appeton nutraceuticals reach consumers for preventive healthcare. Distribution extends to 30+ countries across Southeast Asia (Singapore, Indonesia, Philippines, Vietnam, Myanmar), East Asia (Hong Kong), West Africa (Nigeria), and Europe (Greece), with a stated strategic goal of presence on four continents by 2030. Internally developed proprietary technologies — TAME (micronised topical emulsion), Aeromist (MDI delivering 75% of actives below 5 micron), ColloidTech, TurboShear, and Dose Master — underpin formulation differentiation, and 208 products are registered with Malaysia's NPRA alongside ISO 9001:2015, ISO/IEC 17025, ISO 13485, and MS2424:2012 Halal certifications.

The revenue model is overwhelmingly one-time product sale across five streams (prescription pharmaceuticals, sterile injectables, respiratory devices, OTC, and nutraceuticals) supplemented by international export; pricing is not publicly disclosed and varies by channel and market. FY2026 Q3 unaudited results show a 9-month YTD revenue of MYR 171,983 thousand, implying an annualised run-rate consistent with the >RM100M revenue band for which the company won the MOPI 2024 'Fastest Growing Local Revenue' award covering 2019–2023. The company also pursues biotechnology and academic collaborations for novel therapeutics, biologics, and vaccine development.

Name

Kotra Pharma

Legal name

Kotra Pharma (M) Sdn Bhd

Website

https://kotrapharma.com

Company type

Private

Founded year

1982

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Kotra Pharma (M) Sdn Bhd is a Malaysian pharmaceutical manufacturer (founded 1982, subsidiary of Bursa Malaysia-listed Kotra Industries Berhad) producing nutraceuticals, prescription drugs, sterile injectables, MDIs, and OTC products across 30+ countries from its RM210M PIC/S GMP-certified facility in Melaka.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

akta.pro secondary industries

Herbal & Botanical Supplements (CRADAGAD), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

Keywords

• Pharmaceutical manufacturing
• Sterile injectables
• Nutraceutical supplements
• Metered dose inhalers
• Dermatological preparations

Headquarters

HQ city

Malacca

HQ country

Malaysia

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales, Personnel

Revenue model

1. Pharmaceutical Products: Revenue from Axcel (paediatric care, dermatological care, anti-infective, gastroenterology) and Vaxcel (sterile injectables including antibiotics, anticoagulants, anaesthetics, proton-pump inhibitors) product lines sold to healthcare providers, pharmacies, and hospitals.
2. Nutraceutical Products: Revenue from Appeton health supplements sold to consumers through pharmacies and retail outlets. Products include vitamins, minerals, and health supplements for children, seniors, and expectant mothers.
3. Over-The-Counter Products: OTC products including Creobic (antifungal) and AxPain (pain/fever relief) sold without prescription through pharmacy retail channels.
4. Respiratory Devices: Revenue from Arite brand metered-dose inhalers (MDI) for asthma and COPD treatment.
5. International Export: Revenue from exporting pharmaceutical and nutraceutical products to over 30 international markets including Singapore, Hong Kong, Myanmar, Indonesia, Philippines, Vietnam, Nigeria, and Greece.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Kotra Pharma manufactures and sells pharmaceutical and nutraceutical products across oral and topical preparations, sterile injectables, metered-dose inhalers, and pre-filled syringes. Its portfolio spans the Appeton nutraceutical line (health supplements), the Axcel pharmaceutical line (paediatric, dermatological, anti-infective, and gastroenterology care across 22 therapeutic classes), the Vaxcel sterile injectables line, the Arite respiratory devices line, and OTC products Creobic and AxPain, all produced at a PIC/S GMP-certified facility in Melaka.

Product overview

Kotra Pharma offers a comprehensive portfolio of nutraceutical and pharmaceutical products providing holistic healthcare from pre-natal care to geriatric wellness. The product portfolio includes Appeton (nutraceutical line for health supplements), Axcel and Vaxcel (pharmaceutical lines covering paediatric care, dermatological care, anti-infectives, and gastroenterology), Arite (respiratory devices with Metered Dose Inhaler technology), and OTC products Creobic (fungal treatment) and AxPain (pain and fever relief). The company manufactures with PIC/S GMP compliance and operates the Kotra Pharma Technology Centre (KPTC) with QbD-designed facilities.

Differentiator

Problem solved

Functional benefit

Brands

• Appeton: Nutraceutical line launched in 1989; a household name for health supplements focused on preventive healthcare for children, seniors, and expectant mothers. Awarded Readers' Digest Trusted Brand Award in 2007 and Guardian Most Voted Brands in 2019.
• Axcel
• Vaxcel
• Arite
• Creobic
• AxPain

Products and services

• Appeton Nutraceutical product line providing health supplements for preventive healthcare across all walks of life, including children, seniors, and expectant mothers. Sold through pharmacy retail and consumer channels; awarded Readers' Digest Trusted Brand Award (2007) and Guardian Most Voted Brands (2019).
• Axcel Pharmaceutical product line specializing in oral and topical preparations across 22 therapeutic classes with focus on paediatric care, dermatological care, anti-infective medicine, and gastroenterology. Features innovative taste-masking technology and the proprietary TAME Technology for dermatological preparations. Preferred and recommended by 7/10 physicians for paediatric care.
• Vaxcel Sterile injectable pharmaceutical product line including antibiotics, antifungals, corticosteroids, proton-pump inhibitors, anaesthetics, anticoagulants, and anti-emetics. Products include pre-filled syringes and various injectable formulations for hospital use.
• Arite Respiratory device product line specializing in Metered Dose Inhalers (MDI) for asthma and COPD treatment. Features Aeromist Technology that delivers 75% active ingredients of less than 5 micron for optimal airway deposition. First MDI line commissioned in Malaysia.
• Creobic Over-the-counter antifungal product line specializing in eliminating and treating fungal infections. Formulated with proprietary TAME solution using TurboShear Technology. Available as Creobic (Clotrimazole 1%) and Creobic Gold (Terbinafine 1%), distributed through pharmacy retail.
• AxPain Over-the-counter product for relief of pain and fever. Small-sized, film-coated caplet (8mm) with Paracetamol 650mg that eases swallowing and has no medicinal taste or smell, improving patient compliance. Sold without prescription through pharmacy retail channels.

Quantifiable outcome

• 75% active ingredients of less than 5 micron delivered by Aeromist Technology (vs competitor's 50%)
• +3 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Biotechnology and Pharmaceutical CompaniescoreStrategic or Co-development PartnerKotra Pharma seeks collaboration with biotechnology and pharmaceutical companies in all phases of scientific and technical development for novel therapeutics development. This is an indispensable business strategy for developing novel therapeutics.
• Academic Researchers and InstitutionscoreStrategic or Co-development PartnerCollaboration with academic researchers and institutions for scientific development in biologics, vaccines, and small molecules. Kotra Pharma has collaborated with both local and overseas universities and clinical research centres for clinical trials.
• Healthcare Services or Technologies InnovatorsminorStrategic or Co-development PartnerPartnership with innovators in healthcare services or technologies for development of novel therapeutics and delivery systems.
• Contract Manufacturers (OEM)minorOEM/ Whitelabel/ Licensing PartnerKotra Pharma coordinates new product development and product quality improvement for nutrition products with contract manufacturers. Maintains contract manufacturers' certification records including halal cert, QMS, and registration licenses.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Pharmaniaga Berhad: Malaysia's largest listed pharmaceutical company with manufacturing, distribution, and logistics operations across generic pharmaceuticals, biosimilars, and sterile injectables. Directly comparable to Kotra Pharma as a domestic pharmaceutical manufacturer serving Malaysian hospitals and export markets.
• Duopharma Biotech Berhad: Malaysian pharmaceutical manufacturer specializing in generic prescription medicines, OTC products, and health supplements with PIC/S GMP facilities. Directly competes with Kotra Pharma in hospital formularies, pharmacy retail channels, and halal-certified pharmaceutical segments.
• Apex Healthcare Berhad (Alpro Group): Malaysian pharmaceutical group with manufacturing (Xepa-Soul Pattinson) and pharmacy retail operations. Comparable to Kotra Pharma in branded generic manufacturing and Malaysian pharmacy distribution channels.
• YSP Industries Bhd: Malaysian pharmaceutical manufacturer focused on finished dosage forms including tablets, capsules, and sterile injectables. Comparable to Kotra Pharma's Vaxcel sterile injectable portfolio and hospital channel presence.
• Hovid Berhad: Malaysian pharmaceutical manufacturer producing generic drugs, OTC products, and health supplements with international presence. Comparable to Kotra Pharma in therapeutic coverage (anti-infectives, cardiology, dermatology) and export market strategy.

Emerging players

• Emcure Pharmaceuticals: Indian pharmaceutical manufacturer with diversified portfolio including sterile injectables, oral solids, and biologics exporting to emerging markets. Comparable to Kotra Pharma in hospital-grade sterile injectables (Vaxcel) and emerging market export orientation.

Broad incumbents

• Sanofi Malaysia: Global pharmaceutical company with significant Malaysian presence across specialty pharmaceuticals, vaccines, and consumer healthcare. Competes broadly with Kotra Pharma's Axcel therapeutic portfolio in paediatrics, gastroenterology, and dermatology.
• GSK (GlaxoSmithKline) Malaysia: Multinational pharmaceutical major with established Malaysian operations in respiratory (including MDI products), vaccines, and consumer healthcare. Competes with Kotra Pharma's Arite MDI portfolio in asthma/COPD treatment and broader therapeutic categories.

Regional players

• Daewoong Pharmaceutical: South Korean pharmaceutical manufacturer with strong sterile injectable and biosimilar capabilities targeting Asian export markets. Comparable to Kotra Pharma's Vaxcel pre-filled syringe manufacturing and hospital injectable focus.
• Kalbe Farma: Indonesia's largest pharmaceutical company with prescription drugs, consumer health, and nutraceutical divisions across Southeast Asia. Comparable to Kotra Pharma as an emerging-market pharmaceutical manufacturer with branded generics and health supplement portfolios targeting regional ASEAN markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/kotrapharma

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kotra Pharma